Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium – Yahoo Finance
Presented findings highlight the unique insights that Theralink’s Assay generates to advance breast cancer research and care
GOLDEN, Colo., Dec. 1, 2022 /PRNewswire/ — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced the acceptance of two poster presentations evaluating the potential use and utility of its novel RPPA (Reverse Phase Protein Array) technology at the San Antonio Breast Cancer Symposium (SABCS) 2022.
Mick Ruxin M.D., CEO of Theralink Technologies stated, “We are so pleased to have multiple poster presentations accepted at SABCS this year. During our presentations we will highlight the potential of our innovative RPPA-based technology for clinical molecular profiling of breast cancer patients. With the excitement around advancements in treatment options for patients with HER2 Low metastatic breast cancer, it is important as ever to have clarity on HER2 status. The Theralink Assay for Advanced Breast Cancer can provide additional levels of quantified clarity for patients who need it the most.”
Additional details on the upcoming posters and corresponding abstracts are shown below. Full text of the abstracts are available on the SABCS website here.
Spotlight Poster Presentation:
Title: ‘Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 INC 0 “Ultra Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer.‘
Session Title: HER2 Low: A Sperate Entity? Special Session – Hall 3
Date: Wednesday, December 7, 2022
Time: 9:45 – 11:00 am CT
Poster Presentation:
Title: ‘Impact of the Theralink CLIA Protein/Phosphoprotein Assay on Treatment Selection in Routine Clinical Practice: a Prospective Observational Study in Advance Breast Cancer.’
Program Number: P4-07-51
Session Title: Poster Session #4 – Hall 1
Date: Thursday, December 8, 2022
Time: 7:00 – 8:15 am CT
The Theralink management team welcomes the opportunity to meet with you in-person in San Antonio at SABCS 2022. Please email info@theralink.com if you would like to arrange for a private meeting with Theralink representatives.
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, precision medicine company with a CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink’s technology targets multiple areas of oncology and drug development. In addition to the Company’s first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by Theralink Technologies with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.
View original content:https://www.prnewswire.com/news-releases/theralink-technologies-accepted-to-present-two-posters-at-the-upcoming-san-antonio-breast-cancer-symposium-301691026.html
SOURCE Theralink Technologies
Related Quotes
Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday.
Wedbush on Friday launched coverage of Green Thumb Industries Inc. , Cresco Labs Inc. , Curaleaf Holdings Inc. and Trulieve Cannabis Corp. with outperform ratings. Analyst Gerald Pascarelli said of the four cannabis companies Green Thumb Industries ranks as Wedbush's top pick. "We believe that brighter days lie ahead for the U.S. cannabis industry and that incremental revenues from new states slated to come online for adult use sales, coupled with a normalization in trend in legacy markets, as w
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate.
Horizon Therapeutics PLC is hitting the gas on its Montgomery County expansion — while considering buyout offers from larger pharmaceutical companies. Roughly a year since the Dublin company committed to building a research and development hub in Rockville and nearly two years after it acquired Gaithersburg’s Viela Bio Inc. for $3 billion, it is now deep into the construction of a facility at 9810 Darnestown Road. Horizon, a commercial-stage company developing treatments for rare, inflammatory and autoimmune diseases, says its planned 192,000-square-foot facility will include 60,000 square feet for laboratory space.
As healthcare costs continue to rise, more and more retailers are adding pharmacy and health services in new and creative ways. Heavy-hitting retailers like Walmart and Target have opened pharmacy departments to mixed results, while Dollar General's new CEO expressed interest in integrating healthcare services in its recent quarterly earnings call. Never a company to be left behind, Amazon has made moves to break into the healthcare industry.
But a bigger problem for Beijing may be the number of elderly Chinese who have yet to get their booster shots.
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.
By Faith Ashmore, Benzinga
Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it. Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price. On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.
Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.
Yahoo Finance's Julie Hyman breaks down leading business stories, including the FDA pausing authorization of Eli Lilly's COVID antibody drug, General Electric setting plans for its health care division, and Neuralink looking to test its brain chip on humans in six months.
By Faith Ashmore, Benzinga
The Laundress is voluntarily recalling about eight million laundry and cleaning products that may contain bacteria that can cause respiratory infections among immunocompromised people. The company said it was issuing the recall Thursday after first warning customers on Nov. 17 to stop using its products. The Laundress said last month it had identified “the potential presence of elevated levels of bacteria” in some of its products and was working with the U.S. Consumer Product Safety Commission.
Corporate giants from Amazon to CVS are investing billions into primary-care practices. It’s part of a sweeping shift in U.S. healthcare to a more value-based model. Here’s what that means for doctors, patients and health insurers. Photo illustration: Amber Bragdon
Christina McKnight, now 35, thought little of her symptoms and was only diagnosed after her husband ‘forced’ her to see a doctor
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Preclinical Data on QN-302 Presented at AACR Conference on Pancreatic Cancer In September 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced the presentation of two posters on QN-302 at the AACR 8 th Special Conference on Pancreatic Cancer. The data presented include information on the compound’s safety,
A large study shows that skipping meals and poor meal timing can have harmful effects on health, including shortening life span.
Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."